Is Glucose-6-phosphatase Dehydrogenase Deficiency Associated with Severe Outcomes in Hospitalized COVID-19 Patients?

Overview

Journal Sci Rep

Specialty Science

Date 2021 Sep 29

PMID 34584152

Citations 4

Authors

Nitya Kumar

Abdulkarim Abdulrahman

Abdulla Ismaeel AlAwadhi

Manaf Alqahtani

Affiliations

Soon will be listed here.

Abstract

Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is known to suppress the antioxidant system and is likely to aggravate severity of COVID-19, which results in a pro-oxidant response. This possible association has not been explored adequately in human studies. In this research, we report that the occurrence of non-invasive ventilation, intubation or death-all of which are indicative of severe COVID-19, are not significantly different in hospitalized COVID-19 patients with and without G6PDd (4.6 vs. 6.4%, p = 0.33). The likelihood of developing any of these severe outcomes were slightly lower in patients with G6PDd after accounting for age, nationality, presence of comorbidities and drug interventions (Odds ratio 0.40, 95% confidence intervals 0.142, 1.148). Further investigation that extends to both, hospitalized and non-hospitalized COVID-19 patients, is warranted to study this potential association.

Citing Articles

Associations between COVID-19 and Glucose-6-Phosphate Dehydrogenase Activity in Brazil.

de Almeida Rodrigues M, Monteiro W, Cardoso de Melo G, Dias A, Sartim M, Xavier M Am J Trop Med Hyg. 2024; 110(6):1191-1197.

PMID: 38593787 PMC: 11154054. DOI: 10.4269/ajtmh.23-0148.

Association of Glucose-6-Phosphate Dehydrogenase Deficiency With Outcomes in US Veterans With COVID-19.

Elsea S, Razjouyan J, Lee K, Lynch J, Martini S, Pandit L JAMA Netw Open. 2023; 6(3):e235626.

PMID: 36988953 PMC: 10061239. DOI: 10.1001/jamanetworkopen.2023.5626.

G6PD deficiency-does it alter the course of COVID-19 infections?.

Au T, Wisniewski O, Benjamin S, Kubicki T, Dytfeld D, Gil L Ann Hematol. 2023; 102(7):1629-1636.

PMID: 36905446 PMC: 10006571. DOI: 10.1007/s00277-023-05164-y.

The Possible Role of Glucose-6-Phosphate Dehydrogenase in the SARS-CoV-2 Infection.

Perez-Torres I, Soto M, Guarner-Lans V, Manzano-Pech L, Soria-Castro E Cells. 2022; 11(13).

PMID: 35805067 PMC: 9265820. DOI: 10.3390/cells11131982.

References

Spanakis N, Tsiodras S, Haagmans B, Raj V, Pontikis K, Koutsoukou A . Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents. 2014; 44(6):528-32. PMC: 7127532. DOI: 10.1016/j.ijantimicag.2014.07.026. View

Noor F, Islam M . Prevalence and Associated Risk Factors of Mortality Among COVID-19 Patients: A Meta-Analysis. J Community Health. 2020; 45(6):1270-1282. PMC: 7486583. DOI: 10.1007/s10900-020-00920-x. View

Garg S, Kim L, Whitaker M, OHalloran A, Cummings C, Holstein R . Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(15):458-464. PMC: 7755063. DOI: 10.15585/mmwr.mm6915e3. View

Chu C, Cheng V, Hung I, Wong M, Chan K, Chan K . Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59(3):252-6. PMC: 1746980. DOI: 10.1136/thorax.2003.012658. View

Littera R, Campagna M, Deidda S, Angioni G, Cipri S, Melis M . Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience. Front Immunol. 2020; 11:605688. PMC: 7746644. DOI: 10.3389/fimmu.2020.605688. View

Horby P, Mafham M, Linsell L, Bell J, Staplin N, Emberson J . Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 383(21):2030-2040. PMC: 7556338. DOI: 10.1056/NEJMoa2022926. View

Zhang J, Wu J, Sun X, Xue H, Shao J, Cai W . Association of hypertension with the severity and fatality of SARS-CoV-2 infection: A meta-analysis. Epidemiol Infect. 2020; 148:e106. PMC: 7270484. DOI: 10.1017/S095026882000117X. View

Panepinto J, Brandow A, Mucalo L, Yusuf F, Singh A, Taylor B . Coronavirus Disease among Persons with Sickle Cell Disease, United States, March 20-May 21, 2020. Emerg Infect Dis. 2020; 26(10):2473-2476. PMC: 7510702. DOI: 10.3201/eid2610.202792. View

Wu Y, Tseng C, Cheng M, Ho H, Shih S, Chiu D . Glucose-6-phosphate dehydrogenase deficiency enhances human coronavirus 229E infection. J Infect Dis. 2008; 197(6):812-6. PMC: 7199897. DOI: 10.1086/528377. View

10.

Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I . Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020; 63(8):1500-1515. PMC: 7256180. DOI: 10.1007/s00125-020-05180-x. View

11.

Luzzatto L, Ally M, Notaro R . Glucose-6-phosphate dehydrogenase deficiency. Blood. 2020; 136(11):1225-1240. DOI: 10.1182/blood.2019000944. View

12.

Alkundi A, Mahmoud I, Musa A, Naveed S, Alshawwaf M . Clinical characteristics and outcomes of COVID-19 hospitalized patients with diabetes in the United Kingdom: A retrospective single centre study. Diabetes Res Clin Pract. 2020; 165:108263. PMC: 7283049. DOI: 10.1016/j.diabres.2020.108263. View

13.

Du R, Liang L, Yang C, Wang W, Cao T, Li M . Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020; 55(5). PMC: 7144257. DOI: 10.1183/13993003.00524-2020. View

14.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

15.

Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X . Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 2020; 41(22):2058-2066. PMC: 7314067. DOI: 10.1093/eurheartj/ehaa433. View

16.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

17.

Tong S, Su Y, Yu Y, Wu C, Chen J, Wang S . Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int J Antimicrob Agents. 2020; 56(3):106114. PMC: 7377772. DOI: 10.1016/j.ijantimicag.2020.106114. View

18.

Nkhoma E, Poole C, Vannappagari V, Hall S, Beutler E . The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009; 42(3):267-78. DOI: 10.1016/j.bcmd.2008.12.005. View

19.

Mohammad A, Ardatl K, Bajakian K . Sickle cell disease in Bahrain: coexistence and interaction with glucose-6-phosphate dehydrogenase (G6PD) deficiency. J Trop Pediatr. 1998; 44(2):70-2. DOI: 10.1093/tropej/44.2.70. View

20.

Buinitskaya Y, Gurinovich R, Wlodaver C, Kastsiuchenka S . Centrality of G6PD in COVID-19: The Biochemical Rationale and Clinical Implications. Front Med (Lausanne). 2020; 7:584112. PMC: 7643021. DOI: 10.3389/fmed.2020.584112. View